Another Victory for Beijing Honglin! Got the Consistency Evaluation certified and won in the Government bid!
---By miaoshou.net
Recently, JUPOSHU Amloidipine Besylate Tablets of Beijing Honglin Pharmaceutical Co.,Ltd. (Briefed as Beijing Honglin in the follow text), following the 2 drugs which are JUPOPINE & ROTOFIER, respectively, is certified the Generic Drug Consistency Evaluation ratified by NMPA.
It also makes Beijing Honglin the company with 3 drugs Consistency Evaluation certified in the pharmaceutical industry this year.
In the meanwhile, in the evening of June 23rd, Shanghai Sunshine Medical Procurement All-In-One (SMPA) made public the government bid winners of the 5th round Centralized Procurement of Medicine of China, and LOTOFIER Glipizide of Beijing Honglin was one of the winners by honor.
Enlisted in the Government bid of Centralized Procurement of Drug and won the bid.
Enlisted in the 5th round of Bid of Centralized Procurement of Drug is another good news for Being Honglin.
What is Centralized Procurement of Drug (CPD) ?
Basically it’s a Governmental Bid organized by National & Healthcare Security Administration to facilitate the cost-down process of the price of medicines and high value medical facilities.
Among drugs which have no distinctive difference in quality and medical performance, government will give the bid to the bidder who offer the lower bidding price.
In this round of procurement, 251 items will be selected, 56% of reduction of prince in average is expected, and the procurement amount reaches 55 billion RMB which is the highest in the history, so undoubtedly the competition among bidders is more intensive than usual.
Categories of bid cover major drugs for chronicle diseases such as hypertension, coronary artery disease, diabetes, anti-allergy, ant-infection, diseases of digestive system etc. and the drugs for serious illness like lung cancer, mammary cancer, colon cancer etc. In the category of hypoglycemic drugs, Glipizide Controlled Released Tablets overthrows the others.
Oral hypoglycemic drug is the effect therapy for curing type II diabetes, among them, insulin secretagogues is always one of the top recommended medication of the domestic and overseas drugs directories, in which Glipizide Extended Released Tablets is one of the classic collection.
With the self-developed osmotic-pump controlled released technology, ROTOFIER of Beijing Honlin has high similarity with original drug, and the previous Generic Drug Consistency Evaluation certification further justifies that quality and medical performance of LOTOFIER is consistent to the original drug.
After the tablet taken, water in the body will be penetrated into the inside of the tablet through the membrane and react with the chemical substances, following by a strong osmotic pressure generated from the dissolving matters and the outgrowing pressure derived from the push layer, API is pushed out from the drug layer through the hole opened by the laser driller; and eventually into the patient’s body at a slow and steadier speed.
Therefore the patients only need to take once a day and the drug density in blood can be evenly sustained in 24 hours, steadier blood glucose concentration, less adverse drug reaction, and higher patients compliance.
Therefore, in more than 10 years of time, ROTOFIER has won the confidence of massive diabetes patients. The news that ROTOFIER enlisted in the bid, its significance in the course of market development and the service to the clinical patients are taken to a higher level.
Amlodipine Tablet, A real molecule long-acting antihypertensive drug.
In recent years, due to the changes of lifestyles and diet patterns, number of patients with hypertensive diseases is on the rise.
In view of variety of causes and the lengthy course of treatment, once diagnosed hypertension, patient might need to take the medication lifetime.
Under the circumstance of hypertension, along with the build-up in the minor artery vessel wall and the narrowing process of the cardiovascular, the resistance against the blood flow in the cardiovascular increases, therefore decreases the fluidity of the blood and the flexibility of the artery. Consequently it results in a negative influence in the metabolism of patients.
Eventually the influence of hypertension will lead to the defects of the organs mechanism as a result, and there’s where the fatal diseases come from.
Amlodipine besylate Tablets and Nifedipine Controlled-release Tablets are both common CCB drugs in clinical practice.
Difference between the two medications is that, Amloidipine could be applied directly on the smooth muscles of vascular, specially adapted to the chronicle stable angina pectoris and variant angina pectoris by means of the dilation of the peripheral vascular to decrease the resistance in the cardio vascular.
On the other hand, Nefidipine focus on the escalating the coronary artery, mains cardiovascular and in turns reduce the tension of the smooth muscles of coronary artery, in crease the oxygen supply by increase of blood flow, that’s why it’s highly adapted to the treatment of coronary artery hypertension (Angina of effort), by simultaneously dilating the small arteries and reducing the resistance from tension of the peripheral vascular.
The Original Drug of JUPOSHU Amloidipine Besylate Tablet is called Norvasc, developed and manufactured by Pfizer.
According to the statistics of PDB, Total global market size of Amloidipine Tablets is 6.5 billion dollars and the sales of Norvasc accounts for 1.02 billion. Based on domestic data, the consumption of Amloidipine reached 0.78 billion RMB in the year of 2018, proves that the potential market for Amlodipine is enormous.
JUPOSHU Amloidipine Besylate Tablet, same as Nefidipine Controlled-Released Tablets, it’s a long-acting drug, once a day, not only it enhance the patient compliance but also it minimize the vibration of blood pressure. It’s a good medication to reduce risk of hypertension emergencies and the impacts of major organ failures.
Half-Life Period (Period of time the density of drug reduced in half in the body) of Amloidipine lasts 35 to 50 hours, it’s genuinely a long-acting anti-hypertensive drug, which means the drug doesn’t need to be converted into a formulation to extend the release of API to prolong the duration of effectivity. It depends on nothing but the ingredients of the drug to extend the duration of time the drug density in the blood reaches the peak.
JUPOSHU Amloidipine Besylate Tablet, with superior quality and excellent level of safety and endurance, it’s the fundamental of the combined medication treatment. After the certification of Generic Drug Consistency Evaluation which proves that JUPOSHU has equivalent performance as original drug, will bring another option for patients with hypertensive diseases.
Ready to go! Always making the high qualified generic drugs.
Beijing Honglin, a modern pharmaceutical corporation invested and founded by GoeGoe pharmaceutical Co., Ltd. in the US. Its’ also a GMP certified pharmaceutical manufacture according the latest GMP code (2010 version), equipped with the advanced extended & controlled-released technologies, it’s by all means an advanced & innovative company in China.
Year 2021 is a very productive year in the history of Beijing Honglin.
3 drugs (JUPOPINE, ROTOFIER & JUPOSHU) were Consistency Evaluation Certified, and currently the Certification of JUPOPHONE Ibuprofen Sustained Released Capsule and Kelanmei Lansoprazole Enteric-Coated Capsule are on the way.
In the course of the creation of the domestic clinical drugs alternatives, reduction of the financial burden for the patients, and money-saving for the budget of national healthcare and security administration, Beijing Honglin undoubtedly provide a substantial contribution again & again.
As a very authentic pharmaceutical company, Beijing Honglin is always ready to offer his best to provide affordable and practical drugs. In the meanwhile, in the aspect of innovation and development of domestic drugs, Beijing Honglin carries lots of responsibility to make all the products the best and to contribute the home country by developing the best medicine and help to build up a healthier pharmaceutical industry.
